1μg (R: reducing condition, N: non-reducing condition).
LRRC15/LIB His Tag Protein, Human
LRRC15/LIB His Tag Protein, Human
Price:
Regular price
$192.00 USD
Regular price
Sale price
$192.00 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Species | Human |
| Synonyms | Leucine-rich repeat-containing protein 15, Leucine-rich repeat protein induced by beta-amyloid homolog (hLib), LRRC15, LIB |
| Accession | Q8TF66-1 |
| Amino Acid Sequence | Tyr22-Gly538, with C-terminal His |
| Expression System | HEK293 |
| Molecular Weight | 82-93kDa (Reducing) |
| Purity | ＞95% by SDS-PAGE&>95% by SEC-HPLC |
| Endotoxin | <0.1EU/μg |
| Conjugation | Unconjugated |
| Tag | His Tag |
| Physical Appearance | Lyophilized Powder |
| Storage Buffer | PBS, 5% trehalose, pH7.4 |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
| Stability & Storage |
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles. |
| Reference | O'Prey J, Wilkinson S, Ryan KM. Tumor antigen LRRC15 impedes adenoviral infection: implications for virus-based cancer therapy. J Virol 2008;82:5933–9. 2. Dominguez CX, Müller S, Keerthivasan S, Koeppen H, Hung J, Gierke S, et al. Single-cell RNA sequencing reveals stromal evolution into LRRC15(+) myofibroblasts as a determinant of patient response to cancer immunotherapy. Cancer Discov 2020;10:232–53. 17. Purcell JW, Tanlimco SG, Hickson J, Fox M, Sho M, Durkin L, et al. LRRC15 is a novel mesenchymal protein and stromal target for antibody-drug conjugates. Cancer Res 2018;78:4059–72. |
Background
The leucine-rich repeat-containing protein 15（LRRC15）is a transmembrane protein located on chromosome 3 at 3q29 that belongs to the LRR superfamily, which is involved in cell–cell and cell–ECM interactions. LRRC15 highly expressed in CAFs within the stroma of numerous solid tumors and directly expressed in mesenchymal tumors such as glioblastoma, sarcomas, and melanoma. LRRC15 expression has been shown to be upregulated in C6 astrocytoma cells in response to proinflammatory cytokines (TNFα, IL1β, and IFNγ) and upregulated in fibroblasts in response to TGFβ. LRRC15 is involved in cell–cell and cell–matrix interactions and came into focus as a promising anticancer target owing to its overexpression in mesenchymal-derived tumors such as sarcoma, glioblastoma, and melanoma and in cancer-associated fibroblasts in the microenvironment of breast, head and neck, lung, and pancreatic tumors.
Picture
Picture
SDS-PAGE
SEC-HPLC
SEC-HPLC＞95%
ELISA
Immobilized LRRC15/LIB His Tag, Human (Cat. No. UA010915) at 10.0μg/mL (100μL/well) can bind Samrotamab (Cat. No. UA011138) with EC50 of 6.86-9.73ng/mL.
